Figure 3
From: Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
E5 inhibited the migration of 4T1 cells or human umbilical vein endothelial cells (HUVECs) induced by CXCL12 and the adhesion of 4T1 cells to MS-5 cells. 4T1 cells (a) or HUVECs (c) in the upper chamber were treated with E5 at different concentrations, and the lower chamber contained 200 ng ml−1 of CXCL12. (b) 4T1 cells pre-treated with E5 (10 μM) were seeded in the upper chamber, and the lower chamber was filled with the conditional medium prepared from the MS-5 incubation. (d) MS-5 cells were pre-incubated for 48 h, followed by the addition of 4T1 cells pre-treated with E5 at different concentrations. The CCK-8 assay was applied to calculate the adhesive rate by detecting the cell viability. The data are presented as the means±s.d. (n=4). * represents P<0.05 and ** represents P<0.01, respectively.
